17 kinds of anticancer drugs have been included in the medical insurance, and have been implemented in many parts of the country

According to Sina pharmaceutical, in recent two days, Beijing, Hunan, Gansu and other places have started to implement 17 kinds of anti-cancer drugs into the national basic medical insurance catalog, and announced the proportion of drug price reduction and implementation date On October 10, the state health insurance bureau issued the notice on including 17 kinds of anticancer drugs into the category B scope of the national basic medical insurance, work injury insurance and maternity insurance drug catalog After more than three months of negotiation, 17 kinds of anticancer drugs have been included in the reimbursement catalog of medical insurance The payment standard of most imported drugs after negotiation is lower than the market price of surrounding countries or regions, which will greatly reduce the drug burden of cancer patients in China It is mentioned in the document that the medical insurance bureau organizes experts to negotiate with some anticancer drugs according to the procedure, including 17 kinds of drugs (hereinafter referred to as "negotiation drugs") such as azacytidine into the category B scope of the national basic medical insurance, work injury insurance and maternity insurance drug catalogue (2017 Version) (hereinafter referred to as the drug catalogue), and determines the payment standard of medical insurance (the list is attached) The competent medical insurance departments of each province (district or city) shall not transfer the negotiated drugs out of the catalogue or adjust the limited payment scope At present, in areas where the integration of urban and rural residents' medical insurance has not been realized, these drugs should also be included in the payment scope of the new rural cooperative medical system in time according to the regulations The following is the news released by the human resources and social security bureaus of all regions up to now: Beijing: the drug price has been reduced by as much as 70% since November 15 On November 31, the Beijing human resources and Social Security Bureau issued a new policy for the benefit of the people It is clear that since November 15 this year, all 17 kinds of anti-cancer drugs, including azacitidine, will be included in the reimbursement scope of Beijing medical insurance, and at the same time, the above drugs will be included in the reimbursement scope of outpatient special diseases In addition to the previously included anticancer drugs, a total of 35 national negotiated anticancer drugs were included in the reimbursement scope of Beijing medical insurance, further reducing the burden of drug use for patients According to the Beijing Municipal Bureau of human resources and social security, 12 solid tumor drugs and 5 blood tumor drugs are included in the 17 countries' negotiation on anticancer drugs, involving multiple cancer types such as non-small cell lung cancer, renal cancer, colorectal cancer, melanoma, lymphoma, leukemia, etc Patients use these 17 countries to negotiate anticancer drugs, which are included in the reimbursement scope according to the determined medical insurance payment standard, which includes all expenses jointly paid by the basic medical insurance fund and the insured personnel The medical insurance payment standard of 17 anticancer drugs is valid until November 30, 2020 During the validity period, if the generic drugs of these 17 kinds of drugs are listed, or the actual price of the drugs in the market is obviously lower than the current payment standard, the state will adjust the medical insurance payment standard; after the expiration of the validity period, the state will also adjust the medical insurance payment standard of these 17 kinds of drugs At that time, Beijing will adjust the medical insurance payment standard of relevant drugs in Beijing in accordance with the adjustment of the state Hunan: an average price reduction of 56.7% has been included in the medical insurance payment since November 30 According to the Hunan Provincial Department of human resources and social security, 17 kinds of anti-cancer drugs with an average price reduction of 56.7% will be launched in Hunan Province, and will be included in the medical insurance payment of Hunan Province since November Recently, Hunan Medical Security Bureau issued the notice on including 17 kinds of anticancer drugs into the category B scope of the drug catalog of basic medical insurance, work injury insurance and maternity insurance, which explicitly included 17 kinds of national negotiated drugs into the category B scope of the medical insurance drug catalog of Hunan Province The 17 drugs include 12 solid tumor drugs and 5 blood tumor drugs, which are all clinically necessary, effective and urgently needed by the insured, involving many cancer types such as non-small cell lung cancer, renal cancer, colorectal cancer, melanoma, lymphoma, etc According to Hunan regulations, when the insured patients of the basic medical insurance in each overall planning area are hospitalized according to the regulations, the self payment proportion is set at 30%, and the payment standard (including all the expenses jointly paid by the basic medical insurance fund and the insured personnel) and the limited payment scope specified in this circular are implemented In order to effectively guarantee the supply and rational use of negotiated drugs, Hunan also included 17 kinds of national negotiated drugs into the management scope of special drugs for medical insurance in the whole province This means that in addition to in-patient medication, related patients can also pick up drugs in the special drug agreement drugstore and outpatient clinic of the hospital, and only need to pay for the expenses borne by individuals, and patients who have been recorded can also enjoy the relevant treatment when purchasing drugs from other places Gansu: 17 kinds of anticancer drugs were included in the medical insurance since 18th, according to the notice issued by the Department of human resources and social security of Gansu Province on 29th, and 17 kinds of anticancer drugs, such as azacytidine, were included in the category B of the basic medical insurance, work injury insurance and maternity insurance of urban employees in our province According to the notice, the payment standard of 17 negotiated drugs includes all expenses jointly paid by the basic medical insurance fund and the insured, and each overall planning area will be reimbursed according to the reimbursement proportion of its own overall planning area The stipulated payment standard shall be valid until November 30, 2020, and shall be adjusted in accordance with the relevant provisions of the national medical insurance payment standard after the expiration of the period of validity Before the adjustment, the standard shall still be implemented 17 kinds of negotiation drugs continue to implement the notice on printing and distributing the catalogue of drugs for basic medical insurance, industrial injury insurance and maternity insurance of urban employees in Gansu Province (2017 version) (Ganren shetong [2017] No 423) issued by the Provincial Department of human resources and social security and the notice on Implementing the negotiation results of 36 kinds of national negotiation drugs (ganyi gaiban Fa [2017] No 32) issued by the Provincial Department of human resources and social security Each city and state should further improve the management methods of negotiated drugs, clarify the supply channels and reimbursement channels of negotiated drugs, and take effective measures to ensure the use and reimbursement of negotiated drugs The notice made it clear that the relevant manufacturers of 17 negotiated drugs should complete the online price adjustment to the provincial drug centralized purchasing department before November 18 For the drugs that fail to make the price adjustment as required after the deadline, the basic medical insurance for urban employees will suspend the payment of medical insurance fund The medical insurance payment of 17 negotiated generic drugs shall be implemented in accordance with the relevant provisions of the notice on Forwarding (grst [2018] No 115) issued by the Provincial Department of human resources and social security Fujian: the first province in China to adjust the proportion of medical insurance payment by about 70% In order to reduce the burden of drug use for cancer patients and improve the medical insurance treatment for the insured, Fujian Medical Security Administration Committee (hereinafter referred to as "Fujian Medical Insurance Office") issued a document saying that 17 national negotiated drugs, which were recently included in the category B scope of the national basic medical insurance, work injury insurance and maternity insurance drug catalog, were included in the category B scope of the Fujian medical insurance drug catalog according to the national regulations The limited payment scope shall be implemented from October 25 Fujian became the first province in China to land this round of national negotiation varieties Nine cities and regions implemented it simultaneously On the first day, lung cancer patients successfully received drug reimbursement Fujian cancer patients enjoy the benefits of national health insurance negotiation more than one month in advance In June this year, the State Medical Insurance Bureau launched a new round of special negotiations on the access of anti-cancer drugs to medical insurance After three months of negotiations, 17 drugs were finally negotiated successfully On October 10, the State Medical Security Bureau issued a notice to include 17 kinds of drugs into the category B scope of the catalogue of drugs for national basic medical insurance, work injury insurance and maternity insurance (2017 version) At the same time, it is required that provincial (District, city) drug centralized purchasing institutions should publicly hang the negotiated drugs on the provincial drug centralized purchasing platform according to the payment standard before the end of October 2018 The medical insurance department shall update the information system in time to ensure the implementation before the end of November After the issuance of the document by Fujian medical insurance office, all cities in the province immediately carried out the implementation work, determined that 17 kinds of anticancer drugs negotiated by the state were included in the medical insurance payment scope, determined the medical insurance payment standard, and adjusted the medical insurance payment proportion to about 70% Xinjiang: compared with the average retail price, the average decrease of 17 kinds of drugs reached 56.7% Starting from 0:00 on November 1, azacytidine and other 17 kinds of anti-cancer drugs were included in the category B scope of the catalogue of basic medical insurance, industrial injury insurance and maternity insurance drugs (2017 Edition) of Xinjiang Uygur Autonomous Region and Xinjiang production and Construction Corps, and the payment standard and limited payment scope of medical insurance were implemented according to the national regulations On October 30, the reporter learned from the medical maternity insurance Department of the human resources and Social Security Department of the autonomous region that the 17 drugs were negotiated by the state, and the state health insurance bureau required the provinces to start implementing them before the end of November The autonomous region is one month ahead of the time specified by the state health insurance bureau After 17 kinds of drugs were added into the drug catalog, 2967 kinds of drugs could be reimbursed by the insured in the autonomous region, including 114 kinds of anticancer drugs The 17 drugs included in the drug catalog include 12 solid tumor drugs and 5 blood tumor drugs, all of which are clinically necessary, effective and urgently needed by the insured, involving multiple cancer types such as non-small cell lung cancer, renal cancer, colorectal cancer, melanoma, lymphoma, etc Compared with the average retail price, the average decrease of 17 kinds of drugs is 56.7% The payment standard of most imported drugs after negotiation is lower than the market price of surrounding countries or regions, which is 36% lower on average, greatly reducing the medical cost burden of the cancer insured.